Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 18/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4123923 | 0.89 | ELANE (0.51) | ELANECYP2C9CYP3A4PRTN3 | |
| SCHEMBL4132088 | 0.88 | ELANE (0.53) | ELANECYP2C9NOTUM | |
| SCHEMBL4137740 | 0.82 | ELANE (0.62) | ELANECYP2C9CYP3A4NOTUM | |
| SCHEMBL4398302 | 0.79 | IDH1 (0.55) | ELANECYP2C9CYP3A4NOTUMIDH1 | |
| SCHEMBL4132323 | 0.79 | ELANE (0.71) | ELANE | |
| SCHEMBL4132268 | 0.78 | ELANE (0.70) | ELANE | |
| SCHEMBL2275517 | 0.77 | ELANE (0.77) | ELANECYP2C9CYP3A4NOTUM | |
| SCHEMBL2273394 | 0.77 | ELANE (1.00) | ELANECYP2C9 | |
| SCHEMBL2272159 | 0.77 | ELANE (0.79) | ELANECYP2C9CYP3A4 | |
| SCHEMBL4136719 | 0.77 | ELANE (0.58) | ELANECYP2C9NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105239-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | claimed |
| US-20090105239-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105239-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | SERPINB1, ELANE, MPO | ELANE 2/4885CYP2C9 524/4885CYP3A4 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.